Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Executive Summary
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
You may also be interested in...
Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
South Korea's Aprogen, which has teamed up with Japan's Nichi-Iko, is set to receive an official regulatory approval for its biosimilar infliximab in Japan and launch the product possibly this year, becoming the second Remicade biosimilar to be marketed in the country after Celltrion's Remsima.
Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review
South Korea's Aprogen, which has teamed up with Japan's Nichi-Iko, is set to receive an official regulatory approval for its biosimilar infliximab in Japan and launch the product possibly this year, becoming the second Remicade biosimilar to be marketed in the country after Celltrion's Remsima.
Asia On The Move: Nichi-Iko Names Outsider To Lead Sagent
November has brought a flurry of senior level pharma executive changes in the Asia Pacific region.